A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and Omicron
T. Z. Yuan, C. Lucas, V. S. Monteiro, A. Iwasaki, M. L. Yang, H. F. Nepita, A. G. Lujan Hernandez, J. M. Taft, L. Frei, S. T. Reddy, C. Weber, K. P. Malobisky, R. Mesquita, A. Sato
Abstract
Bispecific antibodies have emerged as a promising strategy for curtailing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune escape. This brief report highlights RBT-0813 (also known as TB493-04), a synthetic, humanized, receptor-binding domain (RBD)-targeted bispecific antibody that retains picomolar affinity to the Spike (S) trimers of all major variants of concern and neutralizes both SARS-CoV-2 Delta and Omicron in vitro.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
- Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease
R. De Gasparo, M. Pedotti, … T. Hatziioannou·bioRxiv·Jan 22, 2021
- Development of Fully Human, Bispecific Antibodies that Effectively Block Omicron Variant Pseudovirus Infections
J. K. Allen, M. A. Gonzalez, … T. Heffernan·bioRxiv·Mar 7, 2023
- A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
L. Hanke, H. Das, … G. M. McInerney·bioRxiv·Mar 20, 2021
- Combating the SARS-CoV-2 Omicron variant with non-Omicron neutralizing antibodies
- An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
X. Chi, X. Zhang, … W. Yang·Signal Transduction and Targeted TherapyPeer-reviewed·Feb 9, 2022